Novel Molecular Approach for Detecting the Changes in Mice Heart After Rolipram Treatment via FTIR Spectroscopy  by Komsuoglu, Ipek et al.
Table 3. There was a good relationship between CAC positive 2 or more
vessels CAD.
None 1 vessel CAD
2 or more vessel
CAD
CAC positive 17 (18,1%) 126 (37,3%) 50 (53,2%)
CAC negative 109 (44,7%) 68 (27,9%) 67 (27,5%)
Total 126 (37,3%) 95(28,1%) 117 (34,6%)
Pearson Chi-
Square value:
33,462,
p<0,0001,
Pearson
Correlation value:
0,304, p<0,0001
Table 4. There was high burden of atherosclerosis in CAC positive patients.
Low Syntax Score
(0-22)
Intermediate S.C
(23-32)
High Syntax Score
(33)
CAC positive 67 (69,3%) 24 (25,5%) 3 (3,2%)
CAC negative 220 (91,9%) 21 (8,5%) 3 (1,2%)
Total 287 (85,4%) 45 (13,5%) 6 (1,8%)
Table 2. Sensitivity, speciﬁty, positive predictivity and negative predictivity
rates of CAC for detection of CAD.
Sensitivity Speciﬁty Positive Pre. Negative Pre.
Value of CAC
for detection
CAD
77,3% 86,5% 81,9% 44,6%
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Purpose: Ischemia-modiﬁed albumin (IMA) is a very sensitive biomarker of
myocardial ischemia before necrosis. IMA has also been found to be elevated in the
setting of oxidative stress, acidosis, hypoxia, inﬂammatory state and sodium and
calcium pump disruptions which are also involved in the pathophysiologic process of
heart failure (HF). However, data about IMA levels speciﬁcally in patients with HF are
still lacking. Dobutamine (DOB) is known to increase myocardial contractility and
oxygen consumption, and thereby may precipitate myocardial ischemia and myocyte
damage. In contrast to DOB, levosimendan (LEVO) does not increase myocardial
oxygen demand and therefore is thought to have cardio protective properties. So, we
aimed to evaluate 1-) serum IMA concentrations in acute decompensated HF and 2-)
the effects of DOB and LEVO treatments on IMA levels.
Methods: This prospective multicenter study was performed at the ﬁve independent
sites. Fifty-nine patients admitted to participating centers with clinical signs and
symptoms of NYHA III-IV acute decompensated HF and LVEF <35% were enrolled
in this study. Blood samples for IMA measurements were obtained from all patients at
baseline and 24 h after the initiation of HF therapy. 18 patients were treated with
guidelines-recommended HF therapy with oxygen, diuretic, vasodilators (control
group), 18 received an additional 24-h infusion of LEVO with a loading dose of 12
mg/kg over 10 min followed by a continuous infusion of 0.2 mg/kg/min (LEVO group)
and 23 had DOB treatment with a continuous infusion of 10 mg/kg/min for 24-h in
addition to optimal pharmacologic therapy (DOB group). A single serum specimen
was also collected from 32 apparently healthy individuals. IMA concentrations wereJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAmeasured by albumin cobalt binding colorimetric assay and results were given as
absorbance units (AU).
Results: In patients with acute decompensated HF, mean serum concentration of IMA
was found to be signiﬁcantly higher than those of apparently healthy population
(0.8940.23 AU vs 0.3790.08 AU, p<0.0001). Overall, IMA levels signiﬁcantly
decreased after 24-h of the initiation of appropriate HF therapy (0.8940.23 AU and
0.8320.18 AU, p <0.013). Furthermore, IMA levels were also found to signiﬁcantly
decrease in control group (1.0410.28 vs 0.8840.15 AU, p<0.041), in LEVO group
(0.7710.18 vs 0.7280.18 AU, p<0.046) and also in DOB group (0.8920.18 vs
0.8200.13 AU, p<0.035).
Conclusions: This study suggested for the ﬁrst time that patients with acute
decompensated HF had elevated levels of IMA when compared to healthy controls
and appropriate HF therapy signiﬁcantly reduced serum IMA levels. The ﬁndings of
this study also demonstrated that both DOB and LEVO treatments did not increase in
IMA levels, suggesting lower potential in inducing myocardial ischemia when used in
recommended doses.
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Introduction: Rolipram is a prototypic inhibitor of phosphodiesterase 4 (PDE4)
which contributes to the regulation of cAMP levels in cardiac myocytes. Recent
studies are focused on the effects of PDE inhibitors on cardiovascular function.
Controversial results exist for the effect of PDE4 on cardiovascular system. Recent
studies have shown that PDE4 inactivation can trigger arrhythmias and lead to the
development of heart failure in mice, but contradictory ﬁndings are also present.
Aim: In the current study, our aim was to investigate the molecular effects of a PDE4
inhibitor, rolipram, on naive mice heart tissue by Fourier Transform Infrared (FTIR)
Spectroscopy. This method monitors vibration groups of different molecules present
in the biological samples so that it gives detailed information about molecular
structure of the system.
Material and Methods: For the experimental part of the study, male Balb-c mice
(totally n¼25) were divided into three groups as control, rolipram 0.1 mg/kg and
rolipram 0.05 mg/kg. Animals treated with subchronic intraperitoneal administration
of rolipram for 15 days. The mice were then sacriﬁced and the heart tissues were
collected for FTIR analysis. The isolated heart samples were studied in 4000-400 cm-1
frequency range with 4 cm-1 resolution. Subsequently, the changes in the FTIR
spectral parameters upon administration of the agents were determined and statistical
analysis was performed.
Results: In this study, both doses of rolipram caused a decrease in lipid, carbohydrate
and protein content of heart indicating breakdown of these biomolecules, which may
be attributed to high cellular activation. Alterations in protein structure were also
observed in treated groups. In addition, heart membrane lipids were more ordered and
more ﬂuid as indicated by the lower frequency and the higher bandwidth values of
CH2 asymmetric stretching, implicating an abnormally increased membrane trans-
portation. Detailed analysis of ¼CH oleﬁnic band showed that rolipram caused
a decrease in the amount of unsaturated lipids in the membrane possibly due to lipid
peroxidation. Another effect of rolipram was observed in hydrogen bonded phos-
pholipids of the membrane structures from frequency changes of the PO2 and the
C¼O modes.
Conclusion: Hence, according to the FTIR spectral parameters subchronic rolipram
treatment led to severe molecular alterations in biomolecules of heart tissue and
membranes. These molecular variations offer molecular information for the action
mechanisms of rolipram on mice heart. Consequently, the ﬁndings of the present study
may suggest that, PDE4 inhibition, could affect the heart tissue which may result in
heart dysfunction and failure.
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Background: Heart failure, increasing incidence, is a serious health problem with
signiﬁcant morbidity and mortality. Early detection of heart failure and timely treat-
ment reduces morbidity and mortality. In recent years, the most extensively studied
diagnostic test is the pro-brain natriuretic peptide (pro-BNP). In addition, many
molecules, which might be useful in the diagnosis of heart failure, have been also
studied. In recent years several studies has utilized lectin-like oxidized LDL receptor-1
(LOX-1) in acute coronary syndromes. The authors suggested that LOX-1 is involved
in apoptosis and facilitates heart failure. In this study, we aimed to evaluate theLS C73
